These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34654425)

  • 1. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
    Kizhakeyil A; Zaini NBM; Poh ZS; Wong BHS; Loh X; Ng AS; Low ZS; Prasannan P; Gong C; Tan MGK; Nagarajan C; Huang D; Lu PW; Lim JQ; Barrans S; Ong CK; Lim ST; Chng WJ; Follows G; Hodson DJ; Du MQ; Goh YT; Tan SH; Grigoropoulos NF; Verma NK
    Mol Cancer; 2021 Oct; 20(1):134. PubMed ID: 34654425
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
    Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
    Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
    J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
    Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
    Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
    Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
    Møller MB; Nielsen O; Pedersen NT
    Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
    Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
    Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
    Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
    Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
    Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
    Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.
    Hardee J; Ouyang Z; Zhang Y; Kundaje A; Lacroute P; Snyder M
    G3 (Bethesda); 2013 Dec; 3(12):2173-85. PubMed ID: 24142927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.
    Wada F; Shimomura Y; Kamijo K; Yamashita D; Ohno A; Himeno M; Maruoka H; Hara S; Ishikawa T
    Leuk Lymphoma; 2022 Jun; 63(6):1484-1487. PubMed ID: 35045767
    [No Abstract]   [Full Text] [Related]  

  • 13. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
    Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
    Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?
    Parrott AM; Haggiagi AM; Murty VV; Bhagat G; Alobeid B
    Hematol Oncol; 2020 Dec; 38(5):817-822. PubMed ID: 32639587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
    Miyazaki K
    Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.
    Gupta M; Maurer MJ; Wellik LE; Law ME; Han JJ; Ozsan N; Micallef IN; Dogan A; Witzig TE
    Blood; 2012 Nov; 120(22):4400-6. PubMed ID: 23018644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma.
    Nakamura S; Seto M; Banno S; Suzuki S; Koshikawa T; Kitoh K; Kagami Y; Ogura M; Yatabe Y; Kojima M
    Jpn J Cancer Res; 1994 Dec; 85(12):1270-9. PubMed ID: 7531681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
    Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
    Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.